Literature DB >> 33569066

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.

Sébastien Lacroix-Desmazes1, Kathleen P Pratt2.   

Abstract

Entities:  

Keywords:  anti-drug antibodies; factor VIII; hemophilia A; immune tolerance induction; protein immunogenicity

Year:  2021        PMID： 33569066      PMCID： PMC7868532          DOI： 10.3389/fimmu.2020.639386

Source DB:  PubMed          Journal:  Front Immunol        ISSN： 1664-3224            Impact factor:   7.561


× No keyword cloud information.
  17 in total

Review 1.  Regulation of antibody responses via antibodies, complement, and Fc receptors.

Authors:  B Heyman
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

Review 3.  The socioeconomic burden of patients affected by hemophilia with inhibitors.

Authors:  Lucia S D'Angiolella; Paolo A Cortesi; Angiola Rocino; Antonio Coppola; Hamisa J Hassan; Adele Giampaolo; Luigi P Solimeno; Alessandra Lafranconi; Mariangela Micale; Sveva Mangano; Giacomo Crotti; Federica Pagliarin; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Eur J Haematol       Date:  2018-07-27       Impact factor: 2.997

Review 4.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

5.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

Review 6.  New therapies for hemophilia.

Authors:  Angela C Weyand; Steven W Pipe
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

7.  ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study.

Authors:  H Marijke van den Berg; Maria Elisa Mancuso; Christoph Königs; Roseline D'Oiron; Helen Platokouki; Torben Stamm Mikkelsen; Jayashree Motwani; Beatrice Nolan; Elena Santagostino
Journal:  Thromb Haemost       Date:  2020-06-22       Impact factor: 5.249

8.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

Authors:  S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

Review 9.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

Review 10.  Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.

Authors:  Angiola Rocino; Massimo Franchini; Antonio Coppola
Journal:  J Clin Med       Date:  2017-04-17       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.